The Zacks Analyst Blog Highlights: General Mills, Kellogg, Novartis, Novo Nordisk and Johnson & Johnson
CHICAGO, Dec. 18, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include General Mills Inc. (NYSE: GIS), Kellogg Company (NYSE: K), Novartis (NYSE: NVS), Novo Nordisk (NYSE: NVO) and Johnson & Johnson (NYSE: JNJ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
Earnings Preview: General Mills
Consumer food giant, General Mills Inc. (NYSE: GIS) is all set to unveil its second quarter fiscal 2013 results before the start of trading on December 19, 2012. The Zacks Consensus Estimate for the second quarter is 79 cents (estimated year-over-year improvement of 3.6%) on revenues of $4.87 billion (year-over-year increase of 5.3%).
First Quarter 2013 Recap
General Mills' first quarter fiscal 2013 adjusted earnings rose 3.1% year on year to 66 cents per share, beating the Zacks Consensus Estimate by 6.5%. The earnings upside was in contrary to management's expectations that earnings would drop from the year-ago levels. The upside was driven by recent acquisitions, low advertising expense and tax rate, and solid international results.
Total revenue increased 5% year over year to $4.05 billion. Revenues mostly benefited from recent acquisitions. Revenues marginally missed the Zacks Consensus Estimate of $4.07 billion.
Agreement of Estimate Revisions
There has been no estimate revision for the current quarter over the last 7 or 30 days. However, for fiscal 2013, 1 of 9 estimates moved down over the past 30 days. None of the estimates has been revised upward. There has been no estimate revision over the past 7 days for the fiscal year.
General Mills did not announce any major news since the announcement of its earnings results in September, which explains the stalemate in estimate revisions.
Magnitude of Estimate Revisions
Given the limited estimate revisions, the consensus estimate for the second quarter has remained static over the last 7 days at 79 cents. However, for fiscal 2013, the estimate has gone down by a penny over the last 30 days from $2.67 to $2.66. The fiscal 2013 estimate has remained static over the last 7 days.
General Mills has surpassed earnings estimates in two of the last four quarters, while missing in two. It recorded a maximum positive surprise of 6.45% in the first quarter of fiscal 2013. On average, the earnings surprise was a positive 1.08% in the trailing four quarters.
We currently have a Neutral recommendation on General Mills. However, the stock carries a Zacks #2 Rank (a short-term Buy rating), reflecting the momentum following the better-than-expected first quarter results.
We are encouraged by the company's strong market share position in some leading food categories, its growing international presence, strategic acquisitions and focus on innovation and brand support. These growth initiatives combined with the cost-saving efforts bode well for the company's long-term growth.
However, we prefer to remain on the sidelines until the U.S. retail volumes improve, the Yoplait yogurt business delivers and the macroeconomic environment recovers substantially.
Peer company Kellogg Company (NYSE: K) carries a Zacks #3 Rank.
U.S. Approval for Novartis' Signifor
The US Food and Drug Administration ("FDA") recently approved Novartis' (NYSE: NVS) Signifor (pasireotide) to treat adults suffering from Cushing's disease for whom pituitary surgery is not an option or has not been effective.
The approval from the US regulatory body did not come as a surprise as in November this year the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) gave a positive opinion on the use of Signifor as a treatment for Cushing's disease.
The FDA's decision was based on positive results from the phase III PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) study. Novartis conducted the study to evaluate the safety and efficacy of Signifor in 162 patients with recurrent Cushing's disease, and newly diagnosed patients with Cushing's disease for whom surgery is not recommended.
Results from the study showed that after treatment with Signifor, patients experienced lower urinary free cortisol (UFC) levels, a measure of disease control. The study also revealed that certain clinical manifestations of Cushing's disease tended towards improvement.
We remind investors that in April this year, Signifor was approved in the EU for the treatment of adults suffering from Cushing's disease who are either ineligible for surgery or have had unsuccessful surgeries. Novartis is currently looking to get the drug approved worldwide.
We are pleased with the US approval of the drug. Signifor, the first FDA approved medicine for the treatment of Cushing's disease, is sure to have a potential market in the US.
Other than Cushing's disease, Novartis is also evaluating Signifor in phase III studies for the treatment of acromegaly syndrome.
Currently, we have a Neutral recommendation on Novartis. Novartis carries a Zacks #3 Rank (Hold) in the short run. However, other pharma companies like Novo Nordisk (NYSE: NVO) and Johnson & Johnson (NYSE: JNJ) carry a Zacks #2 Rank (Buy).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.